JP2013517487A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517487A5
JP2013517487A5 JP2012549291A JP2012549291A JP2013517487A5 JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5 JP 2012549291 A JP2012549291 A JP 2012549291A JP 2012549291 A JP2012549291 A JP 2012549291A JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5
Authority
JP
Japan
Prior art keywords
tumor
cancer
antigen
cells
associated carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012549291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517487A (ja
Filing date
Publication date
Priority claimed from EP10000527A external-priority patent/EP2347769A1/en
Application filed filed Critical
Publication of JP2013517487A publication Critical patent/JP2013517487A/ja
Publication of JP2013517487A5 publication Critical patent/JP2013517487A5/ja
Ceased legal-status Critical Current

Links

JP2012549291A 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用 Ceased JP2013517487A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29673810P 2010-01-20 2010-01-20
US61/296,738 2010-01-20
EP10000527A EP2347769A1 (en) 2010-01-20 2010-01-20 Cancer stem cell markers and uses thereof
EP10000527.1 2010-01-20
PCT/EP2011/000217 WO2011089004A1 (en) 2010-01-20 2011-01-20 Cancer stem cell markers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253064A Division JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Publications (2)

Publication Number Publication Date
JP2013517487A JP2013517487A (ja) 2013-05-16
JP2013517487A5 true JP2013517487A5 (enExample) 2014-02-06

Family

ID=42173400

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549291A Ceased JP2013517487A (ja) 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Country Status (8)

Country Link
US (1) US20120294859A1 (enExample)
EP (2) EP2347769A1 (enExample)
JP (2) JP2013517487A (enExample)
CN (1) CN102753199A (enExample)
AU (1) AU2011208874B2 (enExample)
BR (1) BR112012018132A2 (enExample)
CA (1) CA2786212A1 (enExample)
WO (1) WO2011089004A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2972390B1 (en) 2013-03-14 2017-11-08 The United States Of America, As Represented By The Sectretary, Department Of Health And Human Services Hyposialylation disorders
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
EP3046588B1 (en) 2013-09-17 2022-03-02 OBI Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
MX378944B (es) * 2014-04-18 2025-03-10 Univ New York State Res Found Anticuerpos de antígeno anti-tf humanizado.
CN103969437B (zh) * 2014-04-22 2017-03-22 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP4116329A1 (en) 2014-05-27 2023-01-11 Academia Sinica Anti-her2 glycoantibodies and uses thereof
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI710571B (zh) * 2015-01-24 2020-11-21 中央研究院 腫瘤標記及其使用方法
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3261675A1 (en) 2015-02-25 2018-01-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Sialylation-increasing therapies for diseases associated with oxidative stress
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCANARRAYS AND METHOD OF USE
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
IL262296B2 (en) 2016-04-22 2024-09-01 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018092885A1 (ja) * 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
WO2018094414A1 (en) * 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
EP3601357A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110161241A (zh) * 2019-04-30 2019-08-23 丁晓昆 一种快速检测生物组织切片cosmc基因突变试剂盒
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
CN113461798A (zh) * 2020-03-18 2021-10-01 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
AU2021298824A1 (en) * 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
EP4281778B1 (en) * 2021-01-25 2025-09-17 Uniogen Oy Use of a fuc-alpha(1-2)-gal glycan structure as a biomarker for bladder cancer
JP2024527620A (ja) * 2021-07-16 2024-07-25 ウニヴェルシテ ド モントリオール がん幹細胞に対する新規の腫瘍特異的抗原及びそれらの使用
CN113804531B (zh) * 2021-09-10 2024-02-06 北京大学 一种细胞高活性染色方法
CN115960169B (zh) * 2021-10-09 2026-07-28 清华大学深圳国际研究生院 特异性靶向非小细胞肺癌肿瘤干细胞的多肽及其应用
CN115197915B (zh) * 2022-08-01 2025-08-26 首都医科大学附属北京胸科医院 恶性表型大细胞肺癌细胞株及其应用
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法
CN121319187B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种与cd176蛋白结合的羊驼源纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
WO2007079448A2 (en) * 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
WO2007140011A2 (en) * 2006-05-26 2007-12-06 The Government Of The United States Of America Erythroid progenitor cells and methods for producing parvovirus b19 therein

Similar Documents

Publication Publication Date Title
JP7274469B2 (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
JP6491701B2 (ja) 新規モジュレーターと使用の方法
CN109970856B (zh) 抗lag-3抗体及其用途
Münz et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
JP2022537053A (ja) 抗ｔｉｇｉｔ抗体
JP2013544493A5 (enExample)
JP7450585B2 (ja) ＣＤ６６ｃに特異的に結合する抗体およびその用途
JP2017149720A5 (enExample)
JP2022507294A (ja) Ｃｄｃｐ１－標的化療法
EP2525832A1 (en) Cancer stem cell markers and uses thereof
CN114040774A (zh) 结合肿瘤组织用于诊断和治疗的抗体
WO2015161247A1 (en) Humanized anti-c16orf54 antibodies and methods of use thereof
WO2014068300A1 (en) Anti-s100a4 antibody molecules and their uses
JP2020125352A (ja) 抗−ｃｄ４３抗体およびその癌治療用途
CN110944665A (zh) 用于预防或治疗肺癌的amhrii结合化合物
JP7165855B2 (ja) 骨髄由来抑制細胞関連疾患の予防および治療用途
BR112020023380A2 (pt) anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo isolado, vetor recombinante, célula hospedeira, método para produzir um anticorpo ou um fragmento de aglutinação ao antígeno do mesmo e para tratar ou detectar câncer, conjugado de anticorpo ,e, composição farmacêutica
CN114907478A (zh) 结合lag-3的抗体及其用途
WO2024077774A1 (zh) 一种多功能重组抗体及其制备方法和应用
HK40113728A (en) Combination therapy of claudin 18.2 antagonist and pd-1/pd-l1 axis inhibitor
CN118891287A (zh) 抗cd73的抗体及其应用
HK40009518B (en) Anti-lag-3 antibody and the use thereof
HK40009518A (en) Anti-lag-3 antibody and the use thereof
BR122024015952A2 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos
BR112019009771B1 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos